COVID Sepsis: Causes, Warning Signs, and Organ Damage

Severe COVID-19 can trigger sepsis, a life-threatening condition in which the body’s response to infection spirals out of control and begins damaging its own tissues. Up to 80 percent of patients with severe COVID-19 meet the clinical criteria for sepsis, driven not by the virus destroying cells one by one but by a cascade of inflammation, blood clotting, and immune dysfunction that spreads far beyond the lungs.¹ The result can be failure of organs that SARS-CoV-2 never directly infected, from the kidneys to the brain.

How SARS-CoV-2 Pushes the Immune System Past Its Limits

When SARS-CoV-2 enters the body, the innate immune system detects viral material and fires up an inflammatory response. Immune cells release a wave of signaling molecules, including IL-6, TNF-α, and IL-1β, which recruit more immune cells and amplify inflammation further.² In a well-regulated response, that burst of inflammation clears the virus and subsides. In COVID sepsis, regulation fails. The innate immune system stays revved up while the adaptive immune system, the part responsible for targeted, efficient virus killing, weakens over time. The imbalance means the body keeps pouring out inflammatory signals without effectively clearing the infection.

Researchers have described this as a “cytokine storm,” a state of runaway inflammation in which blood levels of pro-inflammatory cytokines climb far above what is needed for defense. Patients with severe COVID-19 show elevated levels of IL-1, IL-2, IL-6, TNF-α, and several other cytokines, and the degree of elevation correlates with how sick they become.³ While the term “cytokine storm” has been debated in the critical care literature (some researchers argue it oversimplifies), it captures a real phenomenon: patients whose inflammatory signals rise highest tend to fare worst.

At the same time, immune cells that should be fighting the virus become functionally impaired. Monocytes and T cells produce fewer cytokines when stimulated in the lab, and monocytes and granulocytes lose their ability to engulf bacteria effectively.¹ So the paradox of COVID sepsis is simultaneous immune overactivation and immune suppression: the body is inflamed everywhere but fighting the infection poorly.

Endothelial Damage and the Clotting Cascade

One of the features that distinguishes COVID sepsis from a simple respiratory infection is what happens to blood vessel walls. The endothelium, the thin layer of cells lining every blood vessel, takes a beating from multiple directions. The virus’s spike protein binds to ACE2 receptors on endothelial cells and injures them directly. Separately, the complement system, a group of immune proteins meant to neutralize pathogens, can form pore-like complexes on the membranes of endothelial cells, adding to the damage.⁴ Autopsy and lab studies have confirmed widespread complement deposits in the blood vessels of the lungs, skin, and kidneys of COVID-19 patients.⁵

When endothelial cells are damaged, two things go wrong at once. First, the vessel walls become leaky, allowing fluid and proteins to seep into surrounding tissue. Critically ill patients with COVID-19 and sepsis show persistently elevated rates of albumin leaking out of blood vessels, a direct measure of how badly the endothelium is compromised.⁶ Second, injured endothelial cells activate clotting. Platelets stick to exposed areas, thrombin generation increases, and tiny clots form throughout the microvasculature. Clotting factors like fibrinogen, D-dimer, and tissue factor rise, while molecules that normally dissolve clots are suppressed.¹

This process, sometimes called immunothrombosis, can lead to deep vein thrombosis, pulmonary embolism, and stroke in COVID patients.⁷ But even when patients do not develop a large, named clot, diffuse microthrombi throughout the small vessels of the lungs, kidneys, and other organs can starve tissue of oxygen and push organs toward failure.⁸

Warning Signs Clinicians Watch For

COVID sepsis does not announce itself with a single symptom. In the early stages, a patient who appears to have ordinary moderate COVID, fever, cough, fatigue, can deteriorate quickly. Clinicians use bedside scoring systems to catch that deterioration before it becomes catastrophic. The National Early Warning Score (NEWS), which tracks vital signs like respiratory rate, oxygen saturation, heart rate, blood pressure, and level of consciousness, has shown strong predictive power in COVID patients. In one study, NEWS outperformed the older qSOFA and SIRS criteria for predicting both 28-day mortality and critical outcomes such as ICU admission or the need for mechanical ventilation.⁹ The organ-by-organ SOFA score, which requires lab work, also proves useful, particularly for predicting mortality in hospitalized patients outside the ICU.¹⁰

Beyond bedside scoring, blood biomarkers add another layer of warning. Elevated IL-6, the inflammatory cytokine, has emerged as one of the strongest single predictors of a poor outcome. One study found that an IL-6 level above roughly 39 pg/mL predicted unfavorable outcomes with high accuracy, and elevated cardiac troponin, a marker of heart damage, added further predictive power.¹¹ A combination of IL-6, C-reactive protein (CRP), procalcitonin (PCT), and D-dimer together yielded high accuracy for predicting ICU mortality.¹² The practical message is that no single number tells the whole story; clinicians look at the trajectory of multiple markers together.

How Viral Sepsis Looks Different at the Bedside

Viral sepsis from COVID tends to present differently from classic bacterial sepsis. In a multicenter observational study, patients with viral sepsis almost always met sepsis criteria because of respiratory and cardiovascular dysfunction. Over 80 percent of viral sepsis patients scored in the worst range for the respiratory component of the SOFA score at ICU admission, compared with about 42 percent of bacterial sepsis patients. Meanwhile, liver, clotting, and kidney scores were often normal early on; roughly 90 percent of viral sepsis patients scored zero in the liver and coagulation components.¹³ At the molecular level, bacterial sepsis triggers more dramatic changes in certain immune pathways than COVID sepsis does.¹⁴ This matters clinically because a patient with COVID sepsis can look deceptively stable in terms of liver and kidney function early on, even while lung function is collapsing.

How COVID Sepsis Damages the Lungs

The lungs bear the brunt. The hallmark injury is diffuse alveolar damage (DAD), the same pattern seen in acute respiratory distress syndrome (ARDS) from other causes. Autopsy studies show DAD in nearly all patients who die of severe COVID-19 lung disease, with features like hyaline membranes lining the air sacs and organized fibrin deposits.¹⁵ Histologically, COVID-related DAD is largely indistinguishable from DAD caused by other infections or injuries, though COVID lungs tend to show more perivascular inflammation around blood vessels.¹⁶

One early puzzle was that some COVID ARDS patients showed severe drops in blood oxygen with relatively modest-looking changes on chest imaging, something not typically seen in ARDS from other causes.¹⁷ Some of these patients also reported surprisingly little sensation of breathlessness despite dangerously low oxygen levels, a phenomenon called “silent hypoxia.” The discrepancy may partly reflect the microvascular clotting described earlier: tiny clots in lung capillaries can impair gas exchange without producing the kind of visible lung consolidation that shows up clearly on a CT scan.

Organ Damage Beyond the Lungs

The Heart

Myocardial injury, detected by elevated troponin in the blood, was reported in roughly 20 to 30 percent of hospitalized COVID-19 patients in early studies.¹⁸ The damage can come from several angles: direct viral infection of heart muscle cells, inflammation of the endothelium within the heart’s blood vessels, oxygen starvation from microclots, and the broader cytokine storm battering cardiac tissue. Not all of these patients develop clinical heart failure, but elevated troponin has consistently been linked to worse outcomes and higher mortality.

The Kidneys

Acute kidney injury (AKI) is one of the most frequent serious complications of COVID-19 beyond the lungs. A meta-analysis found that roughly 29 percent of hospitalized COVID patients in the US and Europe developed AKI, and in patients who required intubation, the proportion climbed to as high as 78 percent.¹⁹ The kidney damage appears driven by a combination of systemic inflammation, endothelial injury, clotting within the kidney’s tiny vessels, and potential direct viral effects on kidney cells.²⁰ A multi-omics study comparing COVID-19 kidney injury with non-COVID sepsis-related kidney injury found striking similarities between the two, including shared patterns of inflammation, immune cell infiltration, and mitochondrial damage, suggesting that much of the kidney harm in COVID is driven by the sepsis process itself rather than the virus alone.²¹

The Brain

Confusion, delirium, and reduced consciousness are common in COVID sepsis patients and fall under the umbrella of acute brain dysfunction. Sepsis-related brain inflammation has long been associated with cytokine-driven leakage of the blood-brain barrier. In COVID-19, endothelial inflammation within the brain’s blood vessels adds an additional route of injury.²² The result can range from mild “brain fog” to full-blown encephalopathy. In the ICU, delirium in COVID patients is associated with longer stays and higher mortality, just as it is in bacterial sepsis.

The Liver

Liver involvement in COVID sepsis tends to be milder than lung or kidney damage, at least initially. The most common finding is a bump in transaminase levels, markers of liver-cell stress.²³ In ICU patients, however, acute liver injury can become serious. The contributing factors read like a summary of the whole sepsis cascade: low blood flow from hemodynamic instability, oxygen deprivation from respiratory failure, damage to the tiny blood vessels in the liver, the cytokine storm, and even the drugs used to treat the infection.²⁴ Severe hypoxemia, present in more than 40 percent of patients needing oxygen therapy, can trigger a cycle of ischemia and reperfusion in the liver that activates its own local inflammatory response, compounding the damage.²⁵

The Glycocalyx and Why the Damage Runs So Deep

There is a layer of protection most people have never heard of that plays a significant role in COVID sepsis. The glycocalyx is a delicate sugar-rich coating on the surface of endothelial cells, functioning like a non-stick lining inside blood vessels. It helps regulate clotting, controls which molecules pass through vessel walls, and shields the endothelium from direct contact with immune cells. In COVID-19, this coating gets stripped away. Children with multisystem inflammatory syndrome related to COVID (MIS-C) showed clear signs of glycocalyx breakdown, with elevated levels of its shed components in blood and urine, and the degree of shedding tracked with TNF-α levels.²⁶ Lab studies have further linked glycocalyx shedding to the enzyme myeloperoxidase, released by activated white blood cells, and shown that inhibiting this enzyme can reduce the shedding.²⁷ Glycocalyx loss effectively strips the brakes off vascular inflammation and clotting, helping explain why organ damage in COVID sepsis can be so widespread.

Secondary Infections Compound the Problem

The immune suppression side of the COVID sepsis paradox has a dangerous practical consequence: it opens the door to secondary bacterial infections. The combination of an overstimulated but poorly functioning immune system, structural lung damage from viral pneumonia, and increased colonization by bacteria, often drug-resistant ones, creates ideal conditions for superinfection.²⁸ During the pandemic, many ICUs saw a rise in secondary infections by multidrug-resistant organisms, partly driven by heavy antibiotic use in COVID wards. These secondary infections carry their own high mortality and can trigger a second wave of sepsis on top of the viral one.

Treatment Strategies

There is no single drug that reverses COVID sepsis. Treatment targets the various arms of the process. Immunomodulatory drugs aim to tamp down the overactive inflammatory response. Baricitinib, a JAK inhibitor, reduced 28-day mortality in critically ill patients on mechanical ventilation by about 46 percent compared with placebo in a randomized trial.²⁹ A systematic review and meta-analysis confirmed that baricitinib significantly lowered both mortality and the need for mechanical ventilation across multiple studies.³⁰ Combination approaches have also shown promise: one regimen combining inhaled DNase (which breaks up the sticky neutrophil traps that contribute to clotting), baricitinib, and tocilizumab (an IL-6 blocker) was associated with lower in-hospital mortality and shorter hospital stays, and lab work showed the combination blocked the clotting pathway activated by COVID-19 plasma in lung tissue.³¹

Anticoagulation, using blood thinners to counteract the clotting cascade, has been another pillar of treatment. In the HEP-COVID randomized trial, therapeutic-dose low-molecular-weight heparin reduced the combined outcome of blood clots and death in non-ICU patients compared with standard prophylactic doses. Blood clots dropped significantly in the therapeutic-dose group, though the benefit was not seen in patients already in the ICU.³² The timing matters: higher-dose anticoagulation appears to help most when started before patients reach the ICU, likely because the clotting process is easier to interrupt early than to reverse once it is fully established.

Recovery and the Post-Sepsis Shadow

Surviving COVID sepsis is not the same as recovering from it. Patients who make it through often face a prolonged recovery period marked by lingering symptoms that overlap heavily with what is seen after bacterial sepsis. Post-sepsis syndrome (PSS) and post-acute sequelae of SARS-CoV-2 (PASC, commonly called long COVID) share a core set of problems: persistent lung, cardiovascular, kidney, and cognitive difficulties, rooted in the tissue damage and immune disruption that occurred during the acute illness.³³ A study of sepsis survivors found that quality of life improves over the first three months after hospital discharge, but the prevalence of post-ICU and post-sepsis syndromes remains high, with considerable symptom overlap between the two.³⁴

Among the predictors of worse outcomes in COVID sepsis, several are modifiable or at least identifiable ahead of time. Unvaccinated status more than doubled the odds of an unfavorable outcome in one analysis, and higher BMI also independently predicted worse results.¹¹ Greater than 50 percent lung involvement on imaging at admission was another strong predictor. These findings reinforce what has been consistent throughout the pandemic: vaccination and early medical attention remain the most effective ways to prevent the kind of severe disease that tips into sepsis in the first place.

The Glycocalyx as a Potential Therapeutic Target

The recognition that glycocalyx destruction plays a central role in COVID-related vascular damage has opened a line of research that barely existed before the pandemic. Because glycocalyx shedding appears to be driven in part by myeloperoxidase released from activated neutrophils, blocking that enzyme could in theory protect the vascular lining and slow the cascade of leakage and clotting. In laboratory experiments, inhibiting myeloperoxidase reduced shedding of syndecan-1, a core component of the glycocalyx, when endothelial cells were exposed to plasma from COVID-19 patients.²⁷ No approved drug currently targets this pathway for sepsis, but it represents a fundamentally different angle of attack: rather than suppressing the immune response or dissolving clots after they form, it aims to preserve the protective surface that keeps vessels functioning normally. Whether that approach will translate from the lab to the bedside remains an open question, but it reflects how much the pandemic accelerated understanding of what actually goes wrong inside blood vessels during severe infection.